











PET/MRI vs PET/CT in Head and Neck imaging: When, Why, and How? 
Authors:  
Joshua Ryan, MD (Indiana University School of Medicine) 
Vasantha Aaron, MD (Indiana University School of Medicine) 
Justin Sims, MD (Indiana University School of Medicine) 
Corresponding Author:  
Joshua Ryan (ryanjl@iu.edu or jlryanmed@gmail.com) 
Present address:  
Indiana University School of Medicine 
Department of Radiology and Imaging Sciences 
550 N. University Blvd. Room 0663 
Indianapolis, IN 46202 
Conflicts of Interest: The authors do not have any financial conflicts of interest 
pertaining to the subject of the article. 
Key Words: Squamous Cell Carcinoma; PET/CT; PET/MRI; Oncologic imaging; PET; 
Imaging protocols  
Abstract: 
The increasing availability of hybrid PET/MRI systems has led to a breadth of 
new publications and opportunities for use of PET/MRI. While PET/CT has been a 
valuable tool for oncologic staging, including head and neck malignancy, there are 
several theoretical and practical advantages a PET/MRI system would have over 
PET/CT in head and neck imaging. This review article discusses the established role of 
PET/CT, early evidence for the role of PET/MRI, and protocol considerations for both 
PET/CT and PET/MRI as they apply to head and neck imaging.  
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Malignancy in the head and neck encompasses a broad array of diagnoses, 
including mucosal surface (epithelial) malignancies of the sinonasal cavity and 
aerodigestive tract, primary and secondary salivary gland malignancies, thyroid cancer, 
skin cancer, orbito-ocular malignancies, skeletal involvement by tumors, and 
malignancies involving the lymphoid tissues. The most common subtype of head and 
neck malignancy is mucosal surface squamous cell carcinoma (SCCa), which is the 
histologic type in greater than 90 % of mucosal surface malignancies, and may arise in 
the sinonasal mucosa, nasopharynx, oral cavity, oropharynx, hypopharynx, and larynx. 1 
In 2012, a worldwide estimated 300,400 new cases and 145,400 deaths arose from oral 
cavity cancer alone. 2 It is estimated that in 2019, there will be 53,000 new cases of 
cancer within the oral cavity or pharynx diagnosed in the United States.3  Well known 
risk factors for head and neck cancer included tobacco use and alcohol, which are also 
known risk factors for other malignancies in the aerodigestive tract (lung and 
esophagus). 1 Human Papilloma Virus (HPV) is an increasingly recognized risk factor 
for head and neck cancer, which has dramatically changed the demographic of head 
and neck cancer patients and shifted the typical age of onset of head and neck cancer 
downward. 1,4,5 Of note, due to increasing incidence of HPV associated head and neck 
malignancy, the American Joint Committee on Cancer (AJCC) now includes a separate 
category for staging of HPV-related oropharyngeal cancer. 4 
In the primary initial workup of a head and neck malignancy, imaging plays an 
essential role, and is generally believed to be more useful in advanced tumor stages. 4 
TNM staging developed by the AJCC is subtyped into multiple sites of origin. 4 Accurate 
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staging is important in treatment planning and prognosis. Owing to the complex 
anatomy of the head and neck region, imaging plays a vital role in supplementing 
diagnosis, treatment planning, and disease monitoring in head and neck malignancy. 6 
In clinical practice, specific imaging is typically selected on a case by case basis, and 
usually involves contrast enhanced Neck CT or MRI. For patients who are suspected to 
have more advanced disease (stage III or IV), FDG PET/CT is a useful tool that 
provides high sensitivity for distant disease. 1,6,7  
 
Whole body PET/MR imaging systems became available in 2010. 8 Since its 
introduction, hybrid PET/MR has grown in availability and has begun to be adopted for 
clinical use, although is still not widely available in the medical landscape. One of the 
primary theoretical advantages of PET/MRI over PET/CT is the improved soft tissue 
contrast of MRI compared to CT. This is especially advantageous when imaging the 
complex anatomical structures that reside within the head and neck. 8 PET/MRI also 
allows for a significant reduction in radiation dose to the patient compared to PET/CT. 9 
  This chapter will discuss the current role of 18F-FDG PET/CT in head and neck 
imaging and contrast the more established role of PET/CT against the emerging 
technology of hybrid PET/MRI. Additionally, this article will briefly review protocolling for 
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Established role of 18F-FDG PET/CT in head and neck cancer. 
FDG PET/CT is commonly performed in clinical practice for the workup and 
staging of head and neck malignancies. In many cases, patients have already 
undergone CT or MRI and endoscopic biopsy prior to undergoing a PET/CT, and an 
established tissue diagnosis is known. The National Comprehensive Cancer Network 
(NCCN) guidelines generally recommend FDG PET/CT in workup of stage III or IV 
disease, or as clinically indicated for most sites of origin.1   
 
Primary Tumor 
A recent study of 35 patients by Chaput et al. showed greater diagnostic 
accuracy with higher sensitivity of FDG PET/CT (83%) compared to MRI (63%) for 
detection of T1-T2 category head and neck SCCa, suggesting efficacy of FDG PET/CT 
in lower stage disease. 10 When PET is performed with a contrast enhanced CT, 
diagnostic CT images can be obtained from a single examination and may obviate the 
need for additional imaging for staging (CT or MR). 11 Of note, at our institution, all 
PET/CT exams are performed with iodinated IV contrast unless there are medical 
contraindications for the patient (contrast allergy or renal insufficiency). PET/CT 
protocols are discussed in detail later in this chapter 
Nodes and Metastases  
FDG PET/CT has also been established as the optimal imaging study for staging 
of nodal metastases and distant metastatic disease, backed by recommendations from 
the AJCC and NCCN for evaluation in stage III and IV disease (Figure 1). 1,4 A meta-
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analysis by Sun et al. showed greater pooled per neck level sensitivity of FDG PET CT 
(84%) for detection of regional nodal metastases over CT or MR (63 %). 12 In addition, a 
recent prospective cohort study by Rohde et al. demonstrated superiority of PET/CT for 
detection rates of distant metastases and second primary malignancy over the 
combination of radiographs, CT, and MRI based on geographical preferences of Europe 
and US. 13   
Cancer of Unknown primary 
The use of 18F-FDG PET/CT is also recommended for diagnoses beyond the 
workup of a known primary site of malignancy within the head and neck. Notably, 
PET/CT has a role in helping identify the primary site in cancer of unknown primary, 
which is typically discovered as enlarged cervical lymph nodes with pathology of 
squamous cell carcinoma, adenocarcinoma or undifferentiated epithelial tumors (Figure 
2). 1 A meta-analysis by Zhu et al. noted that 18F-FDG PET/CT had an overall detection 
rate of 0.44, pooled sensitivity of 0.97, and specificity of 0.68 for primary site detection 
in an analysis of 7 studies. 14 
Mucosal Melanoma 
18F-FDG PET/CT should also be considered for staging and screening for 
metastatic disease in the setting of mucosal melanoma, which is generally seen in an 
older population with median age at diagnosis 70. 4,15 Mucosal melanoma is a rare 
entity, encompassing only 1.3% of known melanoma cases, with about 55% occurring 
in the head and neck region. 16 Most of the head and neck mucosal melanoma cases 
arise in the paranasal sinuses and nasal cavity. 4 Unfortunately, mucosal melanoma is 
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an aggressive entity, and most patients progress to metastatic disease. 17 Metastases 
can occur most commonly in lung, bone, peritoneum, and central nervous system; thus 
PET/CT is an ideal imaging modality to evaluate for distant metastases. 17 MRI Brain is 
also usually indicated for evaluation of brain metastases in melanoma patients.  
 
Salivary gland malignancy 
According to the AJCC, there is no established role for PET/CT for the evaluation 
of primary salivary gland malignancy, with CT and MR potentially providing a 
complementary role in staging and diagnosing major salivary gland tumors. 4 A recent 
prospective study by Park et al. showed 18F-FDG PET/CT to be useful in the detection 
of metastases and additional primary cancers in these patients, along with a predictive 
role in survival outcomes. 18 This study suggests that expansion of the current role of 
18F-FDG PET/CT in primary salivary gland cancer may be an area of further research.  
Treatment evaluation and post-treatment FDG PET 
In the post-treatment setting following radiation (RT) alone or chemotherapy and 
radiation (CRT), NCCN guidelines state that 18F-FDG PET should be considered after 
therapy in patients who exhibit clinical response to treatment with a wait time of at least 
12 weeks to minimize post-treatment uptake and false positive results (Figure 3). 1 A 
meta-Analysis performed by Gupta et al. showed excellent sensitivity (79.9 %), 
specificity (87.5 %) and negative predictive value (NPV; 95.1 %), but a relatively low 
positive predictive value (PPV; 58.6 %). 19 This meta-analysis suggests that PET/CT is 
a more accurate modality for informing clinical decision making when the results are 
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negative. 19 While it has generally been established that post-therapy 18F-FDG PET/CT 
should occur around 12 weeks or greater post therapy, the NCCN suggests that 18F-
FDG PET/CT can also be considered earlier in patients who have evidence of persistent 
or progressive disease. 1 However, there is currently no well-established role of 18F-
FDG PET/CT in assessing early response while undergoing treatment. 20 
The recently published PET-NECK randomized controlled trial performed by 
Mehanna et al. showed non-inferiority of 18F-FDG PET/CT surveillance after CRT in 
patients with advanced nodal (N2 or N3) disease compared to patients who underwent 
radical neck dissection.21 The results of the PET-NECK study show a viable noninvasive 
alternative for disease surveillance in patients with treated metastases.   
Another recently published multicenter trial by Lowe et al, the ACRIN 6685 trial, 
showed a 18F-FDG PET/CT to have a high NPV (87%) for a clinically N0 neck in 
patients with squamous cell carcinoma. 22 This study also noted that surgical planning 
was changed in approximately 21 % of patients after surgeon review of the PET/CT. 
The findings from this study demonstrate the value of 18F-FDG PET/CT in determining 
treatment course for clinically N0 necks.  
Prognostic value of 18F-FDG PET/CT 
There has also been a focus in the recent literature on the prognostic value of 
18F-FDG PET/CT in patients with head and neck malignancy. The most well-known and 
widely reported semi-quantitative measurement parameter in PET is the maximum 
standardized uptake value (SUV) within a volume of interest.  SUV has been 
established as a prognostic indicator in head and neck squamous cell carcinoma, with 
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increased SUV of primary tumors being a poor prognostic factor. 23 However a recently 
published meta-analysis by Wang et al. demonstrated superior prognostic predictive 
capabilities of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) 
compared to SUV max. 24 It should be noted that TLG and MTV are not yet widely used, 
possibly because they are difficult to perform and require specialized software. 
Regardless of the measurement parameter employed, 18F-FDG PET/CT has 
established itself as an important prognostic tool for clinicians.  18F-FDG PET/CT has 
also shown potential value in the radiation therapy treatment planning, as treatments 
such as intensity-modulated radiation therapy (IMRT) depend on accuracy of tumor 
size.  20 
18F-FDG PET/CT is a versatile imaging modality that can help guide clinical 
decision making in a variety of settings. However, there are known advantages MRI has 
over CT in head and neck imaging, including better soft tissue contrast and spatial 
resolution, and lack of ionizing radiation. Combined with the fact that many patients with 
head and neck malignancy undergo both, these limitations provide a framework for the 
clinical use of PET/MRI in many head and neck settings.   
 
PET/MRI in imaging of head and neck 
Retrospective fusion 
The earliest studies that examined the feasibility of PET combined with MRI in 
head and neck imaging were fusion studies between separately performed MRI and 
PET. Nakamoto et al. published a retrospective fusion study in 2009 that showed the 
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benefit of PET fusion with MRI in post-treatment patients suspected of having disease 
recurrence, though there was minimal benefit in initial staging. 25 Retrospective fusion 
study by Huang et al. showed that fused PET/MR provided greater performance than 
PET/CT, standalone CT, or standalone MRI in detecting tumor size and local invasion in 
advanced buccal squamous cell carcinoma. 26 Kanda et al. performed a retrospective 
fusion study in 30 patients with oral cavity or hypopharyngeal cancer, which showed 
greater accuracy of T category assessment with fused PET/MRI and MRI compared to 
PET/CT, and greater accuracy of N category assessment with fused PET/MRI and 
PET/CT over MRI alone. 27 
Initial experiences with hybrid PET/MRI. 
Boss et al. were the first to publish a study demonstrating the feasibility of a 
simultaneous PET/MRI system in a study of 8 patients. 28 Their results showed no 
image degradation of the accompanying MR images, with the added benefit better 
spatial resolution of PET images performed with MRI as compared to the PET/CT, due 
to the smaller diameter of PET detector ring and smaller scintillation crystal sizes on 
their PET/MRI system. 28 These initial results were supported by the findings of Platzek 
et al., who showed no MRI artifacts in PET images in a 20-person prospective study in 
patients with head and neck squamous cell carcinoma. 29 Another early study showed a 
good qualitative comparison between PET/MRI and PET/CT images and a correlation 
between SUVs between the PET/MRI and PET/CT. 30 Along with correlating SUVs 
between PET/MRI and PET/CT, Covello et al. demonstrated the multiparametric 
abilities of PET/MRI in the evaluation of head and neck imaging (SUVs, diffusion, and 
perfusion parameters). 31 
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PET/MRI vs PET/CT and conventional imaging; The evidence 
TNM staging 
Following the feasibility studies, the next step in research of PET/MRI for image 
quality in the head and neck was to compare PET/MRI to PET/CT and to conventional 
imaging (MRI and CT). Several studies have shown the non-inferiority of PET/MRI in 
staging these malignancies. For example, a prospective study by Kuhn et al. evaluated 
150 patients with head and neck cancer presenting for a PET/CT evaluation.  Using a 
trimodality PET/CT-MR setup, their results showed that contrast enhanced PET/MR 
performed significantly better than contrast enhanced PET/CT in evaluation of primary 
tumors; however, there was no significant difference in evaluation of lymph nodes. 32 
Another study by Platzek et al. noted that there was no significant difference between 
PET/MR and MRI and PET alone in the accuracy of lymph node staging in 38 patients. 
33 A small study of 17 patients by Kubiessa et al. showed no statistically significant 
difference in diagnostic performance (Sensitivity, Specificity, PPV and NPV) between 
PET/CT and PET/MRI in evaluation of malignant findings in patients with head and neck 
cancer.34 Partovi. et al also found comparable results between PET/CT and PET/MRI 
for detection of lymph nodes and metastases in their prospective study of 14 patients 
with head and neck cancer (figure 4). 35  
A small study of 16 patients with laryngeal cancer by Cavaliere et al. showed that 
PET/MRI is useful for the primary staging of laryngeal cancer and is comparable to 
PET/CT. 36 Their study showed a high correlation between imaging findings and 
endoscopic/histological evaluation for PET/MRI. They also reference the ability of MRI 
in determining cartilage invasion in suggesting potential for PET/MRI in the evaluation of 
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laryngeal cancer. 36,37 Cavaliere et al. also discuss the advantages of being able to 
collect metabolic, anatomic and functional parameters in a single imaging study. 36  
Stronger evidence for the use of PET/MRI over PET/CT is seen in a recently 
published prospective study of 113 patients by Chan et al., which recommended the use 
of whole-body PET/MRI as a single imaging modality in the staging of nasopharyngeal 
carcinoma. In this study, PET/MRI outperformed PET/CT and head and neck MRI for T 
category assessment and showed higher PPV for assessment of distant metastatic 
disease. 38 
 
Follow-up imaging and disease recurrence 
The theoretical advantage of PET/MRI over PET/CT may be greatest in the post-
treatment setting, as the superior soft tissue contrast resolution of MRI may provide the 
clinician and radiologist more evidence to determine whether FDG uptake is true 
recurrence, physiologic activity, or expected post-treatment related uptake. To this 
effect, Queiroz et al. suggest that PET/MRI may be superior to PET/CT in evaluating 
unclear FDG findings in follow-up patients with head and neck cancer, but their study 
showed no significant difference in diagnostic accuracy between PET/CT and PET/MRI. 
39 A retrospective analysis by Schaarschmidt et al. showed no significant difference in 
correct classification of incidental radiotracer uptake in the head and neck on PET/MRI 
compared to PET/CT in 81 oncologic patients. 40 In a separate publication, 
Schaarschmidt et al. also noted no significant difference between PET/MRI, PET/CT, 
and MRI in local tumor staging or cancer recurrence in a small study of 25 patients. 41   
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In a study demonstrating the multiparametric capabilities of PET/MRI, Becker et 
al. showed excellent results for detection of recurrent disease and tumor classification of 
PET/MRI performed with diffusion weighted imaging (DWI) in the post-treatment setting. 
42 This study notes the value of concordant imaging results between PET, MRI, and 
DWI in predicting tumor recurrence, and discordant results corresponding to benign 
post-treatment changes. 42 These results differ from an earlier study by Queiroz et al., 
which concluded that DWI was not helpful in the evaluation of head and neck 
malignancy with PET/MRI. 43 They also highlight the findings of Rasmussen et al. that 
18F-FDG uptake and DWI have independent but complementary roles in head and neck 
imaging. 44 Based on the preliminary research, further studies will be necessary to 
define the role of multiparametric imaging as part of a PET/MRI examination in the head 
and neck.  
Cancer of unknown primary and non-squamous cell carcinoma of the head and 
neck.  
18F-FDG PET/CT has been firmly established as a valuable tool in the work-up 
of cancer of unknown primary manifesting as cervical lymph node metastases, and 
PET/MRI hold promise in this setting, as well. 1,14 In a study of 20 patients, PET/CT and 
PET/MRI equally identified 11/20 primary cancer sites. 45 They also noted that PET/MRI 
had superior assessment of cervical lesions on PET/MRI and superior detection of 
pulmonary metastases on PET/CT, although no statistical significance was determined. 
45 To date, no studies have been performed that specifically assess the utility of 
PET/MRI in salivary gland malignancies or mucosal melanoma. This may be in part due 
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to the non-established role in of FDG-PET/CT in assessing salivary gland malignancies, 
and the rarity of mucosal melanoma.  
 
Specific situations where MRI is preferred over CT.  
There are situations in which the superiority of MRI over CT can be used to infer 
that PET/MRI may be a preferred modality to PET/CT. One is the evaluation of 
perineural spread, where MRI is preferred over CT because of its superior soft tissue 
contrast resolution. 46 (Figure 5) In reference to PET/MRI, a prospective study by Sekine 
et al., which used a trimodality PET/CT+ MRI system, showed that PET/MRI detected 6 
cases of perineural spread, while PET/CT detected only 5. 47  
MRI is also the imaging modality of choice in the evaluation of salivary gland 
malignancy and helps with accurate localization and locoregional extension of salivary 
gland tumors, as well as detection of perineural spread. 48 MRI is also generally 
regarded as superior to CT in evaluation of orbital disease, due to superior contrast 
resolution and ability to assess extent of disease involving the orbital compartment, 
perineural spread, and intracranial extension. 49 Evaluation of subtle skull base invasion 
and marrow replacement, along with intracranial extension is also better appreciated by 
MRI, which is currently the gold standard for evaluation of nasopharyngeal carcinoma. 
38 MRI is also the preferred modality when imaging the sella and parasellar region. 50 
Specifically, the superior soft tissue contrast resolution would be better for staging in 
evaluating for carotid encasement and cavernous sinus extension.  
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Another clinical situation is evaluating the oral cavity and oropharynx in patients 
with dental hardware. Streak artifact from CT can limit the diagnostic confidence and 
lesion conspicuity, while MRI can also have signal void due to metallic artifact, it is 
generally less of a hinderance in diagnostic confidence than CT artifact. (Figure 6).  
 
Summary of findings and suggestions for clinical use of PET/MRI  
The first portion of this chapter has briefly reviewed the evidence for the use of 
both 18F-FGD PET/CT and PET/MRI in the setting of head and neck cancer. As 
described, 18F-FDG PET/CT plays a significant and versatile role in head and neck 
imaging, and its recommendation by the AJCC and NCCN in multiple settings further 
emphasizes its established role in medical imaging. However, while the data comparing 
PET/CT to PET/MRI are limited in number of studies and patients per study, the 
preliminary results show that PET/MRI is comparable to PET/CT in multiple settings. It 
is therefore reasonable that PET/MRI should be considered for use in individually 
selected cases where the benefit of MRI is perceived to be of greater than CT.  
Specific examples were PET/MRI could be considered include patients with 
significant dental artifact that hinders the diagnostic confidence of CT. PET/MRI should 
also be considered in patients who have suspected perineural disease or have primary 
tumors that are at high risk for perineural tumor spread, such as salivary gland 
neoplasms, orbital tumors, and skin cancer.  In patients with head and neck malignancy 
who would be deemed to require a separate MRI and PET/CT for staging or restaging, 
PET/MRI can provide the convenience of a “one stop shop” and should be considered. 
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PET/MRI should also be considered in evaluation of locally advanced tumors where 
differentiation between tumor and adjacent structures would have an impact on clinical 
or surgical decision making, including staging of disease. PET/MRI should also be 
considered for primary tumors near the skull base, orbits, oral cavity, or in primary 
nasopharyngeal carcinoma. At our institution, the selection of head and neck cancer 
patients for PET/MRI is typically done in a multidisciplinary approach with 
multidisciplinary tumor boards providing an ideal platform for physician-to-physician 
discussions about the capabilities of PET/MRI and the appropriate selection of patients 
for PET/MRI. 
 
PET/CT protocol considerations 
Background 
PET/CT imaging protocols vary greatly, and imaging of head and neck 
malignancies highlights some of the differences. In this section, we will review the PET 
and CT parameters that can be manipulated in order to optimize head and neck scans. 
More general PET imaging questions, such as appropriate blood glucose levels or 18F-
FDG dosing, will not be discussed. 
CT parameters 
The most fundamental question in protocoling the CT portion of a PET/CT study 
is determining whether the CT should be “diagnostic” or performed only for anatomic 
localization and attenuation correction. The latter “low dose CT” protocol is the most 
common approach in the United States with some predominantly academic institutions 
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favoring the former. Some institutions perform a combination of both low dose and 
diagnostic CTs. For example, performance of a low dose CT from the skull to the thigh 
may be followed by a dedicated, diagnostic, breath-hold chest CT in patients with lung 
cancer.  
Localization and attenuation correction protocols employ low mAs (30-80) and 
varying kVp settings and may reduce radiation dose by as much as 50-80% 51; 
however, they come at the cost of increased noise and artifact and do not typically use 
iodinated contrast. This means that there is little soft tissue contrast and minimal 
information regarding tumor characterization or extent of local spread can be gleaned 
from such studies.  
The exact definition of diagnostic CT may differ among radiologists; however, 
adequate spatial resolution with acceptable signal to noise ratio, increased soft tissue 
contrast, and enough radiation dose to allow for diagnostic characterization of 
pathologic processes are necessary to consider a study diagnostic. 52 This requires 
higher mAs, which is ideally modulated based on the patient topogram, and in patients 
without contraindications, iodinated contrast administration. The advantages of contrast-
enhanced CT (CECT) over non-contrast CT (NECT) in evaluating many pathologic 
processes are well established and include increased lesion conspicuity, lesion 
characterization, and diagnostic confidence. However, there are very few clinical studies 
evaluating its benefits in the setting of 18F-FDG PET/CT and no study specifically 
addresses this question in the setting of head and neck malignancies. There are a few 
studies of other tumor sites, which have shown the benefits of using CECT with PET 
imaging. A small retrospective study comparing CECT versus low dose, NECT PET/CT 
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whole body imaging in patients with different tumor types showed that CECT added 
value to a majority of scans. 53 The greatest benefit in this study was in exact 
localization of abnormal 18F-FDG uptake on the PET and precise delineation of tumor, 
which led to a change in management in 21% of patients. The same group confirmed 
that CECT PET/CT changed the delineation of primary tumor in 63% of patients with 
non-small cell lung cancer compared to NECT PET/CT imaging, and in 20% of patients 
the CECT led to the detection of other important clinical findings. 54 Another small 
retrospective study showed that CECT PET/CT more accurately identified nodal 
metastatic spread of rectal cancer over NECT PET/CT. 55  
To date, only two studies has been published comparing CECT and NECT 
PET/CT in head and neck malignancies, however, neither study was designed to 
evaluate the benefits specific to CECT.  One study was performed to determine whether 
the use of CECT would change interpretation of the PET portion of the scan compared 
to low dose NECT PET/CT due to potential differences in attenuation correction. 56 
While the study authors concluded that there was no clinically significant difference in 
interpretation of the PET when using CECT or NECT for attenuation correction, the 
study did not address changes in interpretation or management based on the CTs 
themselves.  The second study compared whole body NECT PET/CT to dedicated 
head/neck CECT PET/CT. 57 The dedicated head/neck CECT PET/CT was performed 
after longer equilibration compared to the whole body NECT PET/CT. In addition, the 
PET was obtained over a longer time period in the dedicated protocol and other PET 
acquisition and reconstruction parameters were altered as well. This study design 
confounded the ability to determine whether the CECT itself led to improved detection of 
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nodal metastases or NECT when performed with PET/CT. Regardless, the study did 
determine that dedicated head/neck CECT PET/CT identified more cervical nodal 
metastases compared to whole body NECT PET/CT and suggests that optimizing both 
PET and CT protocols may significantly alter interpretation and patient management.  
We do know that identifying and defining perineural spread, cartilage 
involvement, necrosis, and nodal extracapsular extension of tumor is crucial in the 
staging and treatment planning of patients with these malignancies and may only be 
delineated with diagnostic contrast-enhanced CT or MRI. CECT performed with PET 
may yield all the necessary information and negate the need for additional, separately 
performed contrast-enhanced CT or MRI, which lead to additional cost and medical 
visits for the patient. Another reason to consider CECT over NECT PET/CT in head and 
neck malignancies is the potential for avoiding false negative interpretations. Cystic and 
mucinous tumors or cystic nodal metastases may show little uptake of 18F-FDG and 
may not be identified or characterized as abnormal based upon the PET data alone 
(Figure 7). Finally, the ability to reconstruct the diagnostic CT into sagittal and coronal 
views, which are standard series for all head/neck imaging at our institution and review 
the images as fused and unfused data sets gives additional, useful information to 
interpreting physicians.  
There are pros and cons to both low dose NECT and diagnostic CECT PET/CT 
protocols.  The major benefits to performing low dose NECT with PET include lower 
radiation dose, limited pre-scan patient evaluation, minimal CT training for 
technologists, and no need for physician presence during scans. As mentioned 
previously, CT images are noisy and show increased artifact without additional 
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information beyond basic localization of tumor sites. Diagnostic CT protocols employing 
intravenous contrast require fully trained technologists in both PET and CT, pre-scan 
evaluation of renal function and contrast allergies, physician presence in case of allergic 
reaction, and increased radiation dose to the patient. In addition, if iodinated contrast is 
administered, interpreting physicians must be aware of possible pitfalls to interpretation. 
While there is no clinically significant change in SUVs when CECT is used for 
attenuation correction of the PET data, artifacts can arise due to large collections of 
contrast.58,59 For example, contrast pooling within a vein may lead to overcorrection of 
the PET data and what appears to be focal accumulation of the radiopharmaceutical. 
Careful evaluation of the underlying CT images and review of the non- attenuation 
corrected PET data are required to determine whether the “hot” spot is a true pathologic 
lesion or artifact (Figure 8).  
 
PET parameters 
There is also flexibility in protocoling the PET portion of PET/CTs for head and 
neck malignancies. The simplest protocol includes a CECT or NECT skull to thigh CT 
followed by a skull to thigh PET. In this protocol, there is no separate, dedicated neck 
imaging. This protocol is fast, minimizes the possibility of patient motion, and potentially 
exposes patients to the least amount of radiation. In head and neck malignancies, 
dedicated head and neck PET images commonly are obtained at a delayed time point 
after performance of the skull to thigh PET/CT. Several studies have demonstrated 
increased sensitivity for detection of small nodal metastases with these types of 
protocols, however the equilibration time after 18F-FDG injection varies widely from 60 
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to 150 minutes (Figure 9). 57,60,61 At least one study has shown that dedicated, delayed 
neck PET/CT can lead to decreased specificity in detection of lymph node metastases, 
presumably because reactive nodes demonstrate abnormal uptake.62 
Most dedicated head and neck PET acquisitions include longer bed times with 
reconstructed smaller field of view and higher matrix/decreased pixel size compared to 
the whole-body PET scan. For example, a dedicated neck PET protocol may include 6-
8 minutes/bed with a 30 cm field of view and 256 x 256 matrix, while the skull-thigh PET 
protocol may employ 2-4 minutes/bed with a 50 cm field of view and 128 x 128 matrix. 
The higher number of counts obtained with the longer bed time in the dedicated PET 
should compensate for the smaller pixels and potential for increased noise. In addition, 
decreasing the size of the field of view without changing the reconstruction matrix or 
even increasing it improves spatial resolution. Slice thickness and amount of zoom 
should be matched with the dedicated CT performed with the PET as well. 
If a dedicated neck PET/CT is performed separate from the skull to thigh images, 
established protocols include performance of a skull to thigh low dose, NECT PET/CT 
followed by the dedicated neck PET/CT, which may also be performed as a low dose, 
NECT PET/CT or as a diagnostic, CECT PET/CT. Performing the dedicated PET/CT 
after the skull to thigh allows for longer equilibration time. Alternatively, the dedicated 
neck PET/CT may be performed after a clavicle to thigh PET/CT or vice versa. In this 
protocol, the patient’s arms are down for the neck portion of the study, which limits 
beam hardening and streak artifact on the CT and, therefore, subsequent artifact on the 
attenuation corrected PET images. While the technologist is setting-up the clavicle to 
thigh portion of the study, the patient is instructed to raise the arms above the head, 
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which then limits artifact upon scanning of the torso. In addition to producing images 
with significantly less artifact, this protocol decreases radiation dose to the neck, which 
is included in only one CT scan. Finally, parameters such as field of view and 
reconstruction matrix can be optimized for the dedicated neck PET/CT and adjusted for 
the clavicle to thigh PET/CT, which may require different parameters such as a larger 
field of view. 
PET/CT Protocol with Diagnostic CECT 
There are many ways to optimize both the PET and the CT protocols in the 
imaging of head and neck malignancies. At our institution, we perform clavicle to thigh 
PET/CT without contrast followed by dedicated orbit to aortic arch, CECT PET/CT of the 
neck, which closely mirrors the parameters of standalone diagnostic neck CTs. For 
example, the soft tissue neck CT protocol at our institution on a 256 slice Philips iCT 
scanner includes scanning at 120 kVp, 250 mAs, 0.993 pitch, and 0.75 s rotation time 
with 2 mm slice thickness at 2 mm intervals 70 seconds after the intravenous 
administration of contrast with axial, sagittal, and coronal reconstructions. This protocol 
is replicated as closely as possible in our dedicated CECT neck PET/CT.  
There are advantages and disadvantages to varying CT and PET parameters in 
patients with head and neck malignancies, and each patient’s unique circumstances 
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PET/MRI protocol considerations 
Background 
Hybrid imaging with PET/MR presents unique protocol challenges not present in 
either standalone imaging technique. One of the initial technical challenges to be 
overcome for clinical PET/MRI was the need for attenuation correction of the PET 
images. PET imaging is uniquely affected by the effects of attenuation, resulting in 
images with dramatically fewer counts in the middle of the imaged object relative to the 
periphery. With hybrid PET/CT, the CT can serve as a quickly acquired, accurate 
attenuation (u) map used for attenuation correction of the images. When CT based 
attenuation correction is utilized, attenuation values of tissues are derived from their 
measured CT numbers, corrected for the expected attenuation values of 511 KeV 
photons.63 The CT-based method of attenuation correction has superseded older 
emission-based methods that used radioactive sources to generate attenuation maps 
due to the ubiquity of PET/CT and the significant lengthening of imaging times created 
by emission methods.  
MRI does not provide a similar analogous source of attenuation correction due to 
the fact that MR signal is derived from tissue hydrogen density and relaxation properties 
rather than the attenuation of x-rays. 64 For a set of MR images to serve for attenuation 
correction of the PET data, segmentation maps must be generated, most commonly 
from a DIXON sequence. This sequence is used to segment tissues into air, lung, fat, 
and soft tissue. Linear attenuation maps based on the expected attenuation of 511 keV 
photons in the segmented tissues can then be used to perform attenuation correction of 
the PET images (figure 10). A fifth tissue—bone—can be added to the attenuation 
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correction algorithm based on atlas data. This helps to avoid the quantitative errors 
introduced when the attenuation effects of bone are ignored, however, errors can still 
occur when an individual patient’s bone anatomy deviates significantly from atlas data. 
65 In addition, errors can be introduced due to incorrect tissue segmentation at air tissue 
interfaces—for example in the paranasal sinuses (figure 11). 66 There is continued 
disagreement among experts regarding whether the quantitative errors introduced by 
MR based attenuation are clinically significant. 67 
The additional sequences required for accurate attenuation correction of the 
images and the time-consuming nature of MRI relative to CT place a critical emphasis 
on the need to develop an efficient set of PET/MRI protocols. It is therefore necessary 
to be judicious with the sequences selected for imaging. 
PET/MRI protocol structure and oncologic protocols in the head and neck 
A general PET/MRI protocol structure is as follows. After an equilibration period 
(typically at least 45 minutes), the patient lies in the PET/MRI gantry (Figure 12). Once 
localizer MRI sequences are obtained, PET and MRI data are obtained concurrently in 
sequential PET “beds.” While PET data are acquired—typically 2 to 5 minutes of PET 
data at each bed—basic MRI sequences are obtained in the anatomic regions of each 
PET bed. These consist of localizer, attenuation correction (AC) MR sequences 
(typically DIXON), and a wide field of view sequence designed to depict the relevant 
anatomy (we use coronal T2 weighted single shot fast spin echo images). These MRI 
sequences are designed to fit within the time frame of PET imaging, and typically occur 
over a time frame of 15 to 20 minutes. Once the whole-body PET/MR imaging has been 
completed, dedicated MRI of the primary region of interest is acquired with the imaging 
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protocol tailored to help answer the current clinical question, usually with a slightly 
abbreviated list of sequences to prevent an excessively long duration of imaging. During 
this period, an additional longer PET acquisition is acquired, resulting in a set of PET 
images with higher image quality made possible by the longer duration of imaging. 
A typical head and neck oncologic PET/MR protocol at our institution begins with 
skull to thigh PET/MR imaging beginning at the top of the skull and proceeding to the 
mid thighs. This is then followed by a dedicated neck or brain MRI tailored to answer the 
relevant clinical questions (e.g., presence of perineural tumor spread, intracranial 
extension of tumor, etc). For example, a neck PET/MRI (Table 1) to evaluate a 
malignancy of the suprahyoid neck would consist of axial and coronal T1 non-fat 
saturation fast spin echo (T1 non-FS FSE) and T2 fat saturation fast spin echo (T2 FS 
FSE) images. This would be followed by diffusion weighted imaging in the area of 
clinical concern. After gadolinium administration, a spoiled three-dimensional gradient 
echo sequence (VIBE on Siemens scanners, LAVA on GE) is obtained, and axial and 
coronal images are generated. PET acquisition continues throughout most of the 
duration of the neck sequences. This is then followed by axial breath-hold spoiled 
gradient echo sequences at mid inspiration at each of the PET bed regions. We have 
found that these sequences only minimally lengthen the examination and facilitate 
comparison with previous and future PET/CT imaging in the axial plane. 
A facial oncologic PET/MR protocol (Table 2) consists of the above sequences 
centered on the facial region, though a three-dimensional FLAIR sequence of the brain 
may be added if there is concern for intracranial involvement. A general orbital PET/MRI 
protocol consists of axial and coronal T1 FSE, coronal T2 FSE, three-dimensional T2 
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SPACE of the orbits, and axial and coronal gadolinium enhanced T1 FS FSE 
sequences. An oncologic brain protocol (Table 3) would consist of 3D T1 high resolution 
spoiled gradient echo sequence (MPRAGE on Siemens scanners, SPGR on GE 
scanners), Axial FLAIR, Axial T2 FSE FS, Axial DWI, and contrast-enhanced 3D 
MPRAGE or SPGR sequences. I 
It should be noted that at our institution, all head and neck PET/MRIs are 
protocolled with input of both nuclear medicine and head and neck radiologists, who 
contribute expertise to a patient-specific protocol that is geared toward answering 
specific staging-related questions. After completion of imaging, this collaborative 
approach continues with joint read outs of cases by both neuroradiologists and nuclear 
radiologists. An example case is depicted in Figures 13 through 15. This case study of 
PET/MR imaging in the initial staging of marginal zone lymphoma highlights the 
complementary nature of information derived from PET and MRI imaging. The joint 
interpretation of this case resulted in the correct identification of perineural tumor spread 
by the interpreting neuroradiologist as well as the identification of widespread areas of 
intramuscular and subcutaneous lymphomatous infiltration by the nuclear radiologist.  
In summary, a clinical PET/MRI protocols begins with whole body PET/MRI 
imaging consisting of abbreviated MRI sequences designed to allow attenuation 
correction and provide basic anatomic information in a similar amount of time as clinical 
PET/CT. This is followed by additional MRI sequences that are designed to answer the 
clinical question in the area of interest. This strategy typically allows a clinical PET/MRI 
to be completed in under an hour, allowing the radiologist to answer the question at 
hand in a time frame acceptable for clinical imaging. 
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 PET/CT is an established modality in oncologic imaging and is widely used in 
head and neck imaging. The increasing availability of PET/MRI in the medical 
landscape raises the question about which modality would be most useful in head and 
neck oncologic imaging. The early literature for PET/MRI largely shows non-inferiority 
when compared to PET/CT in head and neck imaging, and some studies show 
advantages of PET/MRI over PET/CT in certain situations, such as the evaluation of 
nasopharyngeal carcinoma. PET/CT and PET/MRI have separate and unique protocol 
considerations in regard to head and neck imaging.  
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Figure 1: PET/CT and MRI Nodal Evaluation in a patient with recurrent nasopharyngeal 
carcinoma. Fused axial FDG-PET/CT (A) shows a hypermetabolic right retropharyngeal 
lymph node (black arrow). Unfused CECT (B) shows corresponding enhancing 
retropharyngeal lymph node (black arrow). Pre contrast T1-weighted precontrast image 
(C) shows the metastatic lymph node (blue arrow) to have similar signal intensity to 
adjacent longus colli muscle. Axial T1-weighted post contrast fat-saturated image (D) 
shows enhancement of the nodal metastasis (blue arrow), along with enhancement into 
the adjacent longus colli muscle (red arrow), suggestive of extra nodal extension. There 
is also enhancement of the soft tissues adjacent to the right internal carotid artery 
(yellow arrow), compatible with arterial encasement. 
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Figure 2: Cancer of Unknown Primary in a patient with palpable right supraclavicular 
mass. Biopsy showed metastatic squamous cell carcinoma without known primary. 
Fused axial FDG-PET/CT (A) for staging shows a right supraclavicular mass (green 
arrow) with peripheral hypermetabolism and central necrosis. The primary site of 
malignancy was not identified on this PET/CT. Fused axial FDG-PET/CT (B) also shows 
an additional, small, hypermetabolic metastasis noted in the right gluteus maximus (blue 
arrow). Unfused axial CECT (C) at the level of the lesion shows the gluteal metastasis is 
not visible on CT alone (yellow circle).   
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Figure 3: Treatment Response with staging and post chemotherapy and radiation 
treatment FDG-PET/CTs in a patient with T3,N0,M0 Squamous cell carcinoma of the 
right palatine tonsil and base of tongue. Fused axial FDG-PET/CT (A) for staging shows 
a hypermetabolic right palatine tonsil and base of tongue mass (red arrow). Fused axial 
FDG-PET/CT 3 months post completion of chemotherapy and radiation (B) shows no 
residual hypermetabolic activity in the right tonsillar fossa (yellow circle), compatible 
complete local response to therapy. Unfortunately, 3 month post therapy fused axial 
FDG-PET/CT (C) also shows a new, hypermetabolic and partially necrotic left upper 
lobe mass compatible with distant metastasis and progression of disease (blue arrow). 
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Figure 4: PET/MRI with lymph node metastases in a patient with oropharyngeal 
squamous cell carcinoma. Fused coronal FDG-PET/MRI with T1-weighted post contrast 
fat-saturated image shows mildly FDG avid cervical lymph nodes (green arrows) due to 
nodal metastases. 
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Figure 5: PET/MRI with perineural tumor spread in a patient with squamous cell 
carcinoma arising in the maxillary sinus. Fused coronal FDG-PET/MRI with T1-weighted 
post contrast fat-saturated image (A) shows a hypermetabolic, enhancing mass in the 
left maxillary sinus with local extension. Coronal T1-weighted post contrast fat-saturated 
image (B) shows soft tissue thickening and enhancement along the superior and inferior 
orbital fissures (yellow arrow), which is markedly FDG avid on the fused FDG-PET/MRI 
(C) compatible with perineural tumor spread. 
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Figure 6: Dental artifact in a patient with suspected recurrent squamous cell carcinoma 
in the right palatine fossa on clinical exam. Axial CECT (A) shows streak artifact from 
dental amalgam limiting evaluation of the oropharynx, although there is subtle fullness 
of the right palatine fossa in the location of clinically suspected recurrence. Axial T1-
weighted post contrast fat-saturated image (B) obtained during FDG-PET/MRI 
acquisition shows reduction in metal artifact from dental amalgam compared to CT, 
allowing the asymmetric soft tissue thickening of the right palatine tonsil to be better 
appreciated. Fused axial FDG-PET/MRI with T1-weighted post contrast fat-saturated 
image (C) shows avid FDG uptake in the area of masslike thickening of the right 
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Figure 7: Primary tumor and cystic nodal metastasis evaluation. Axial CECT (A) 
demonstrates fullness of the left nasopharyngeal mucosa with heterogeneous 
attenuation. A small, hypodense lesion in the right retropharyngeal space (yellow arrow) 
is able to be appreciated due to the surrounding, enhancing normal tissues and 
corresponds to a necrotic retropharyngeal lymph node. Fused axial FDG-PET/CT 
demonstrates a hypermetabolic left nasopharyngeal mucosa consistent with primary 
malignancy. The necrotic right retropharyngeal lymph node does not show FDG avidity, 
but remains suspicious for malignancy given its characteristics on CT. 
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Figure 8:  Attenuation Correction. Axial 18F-FDG PET attenuation corrected image (A) 
demonstrates two foci of abnormal uptake in the right supraclavicular fossa (white 
arrows). Axial 18F-FDG non-attenuation corrected PET (B) shows minimal uptake in the 
right supraclavicular fossa on the same slice (black arrows). Review of the fused axial 
18F-FDG PET/CT dataset at the same level (C) demonstrates a large bolus of iodinated 
contrast material in the right supraclavicular fossa (yellow arrow) causing artifactual 
accumulation of radiotracer activity. 
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Figure 9: Added value of PET/CT fusion. Axial 18F-FDG PET image (A) through the 
neck does not demonstrate a definitive focus of abnormal uptake. Axial non-contrast CT 
through the same level (B) shows no pathologically enlarged lymphadenopathy. Fused 
axial 18F-FDG PET/CT without contrast (C) shows a small left level 2A lymph node with 
low uptake (yellow arrow), which is difficult to determine whether it is abnormal 
metastatic node or a reactive lymph node. Fused axial 18F-FDG PET/CT with iodinated 
contrast in the same patient more conspicuously demonstrates abnormal, round, mildly 
hypermetabolic left level 2A lymph node metastasis (white arrow). 
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Figure 10: Tissue Segmentation Map. Coronal MR tissue segmentation map derived 
from DIXON MR sequence and Atlas data. This map is used for attenuation correction 
of the PET data. Note that the spine, pelvis, and femora are included in the 
segmentation map, however, the upper extremity bones are not segmented in the 
software algorithm. 
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Figure 11: Tissue Segmentation Map of the face with incorrect segmentation. Coronal 
MR tissue segmentation map of the skull shows portions of the frontal bone, orbits, and 
paranasal sinuses to be incorrectly segmented as soft tissue. The air-filled paranasal 
sinuses are also mostly incorrectly segmented. 
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Figure 12: PET/MR Unit. Siemens (Siemens Healthineers AG, Munich, Germany) 
Biograph MMR PET/MR scanner is shown. The gantry houses an integrated PET 
detector ring which allows concurrent PET and MR sequence acquisition. 
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Figure 13: Masticator Space mass. Fused axial PET/MRI with T1-weighted post 
contrast fat-saturated image demonstrates an avidly-enhancing, FDG avid mass (yellow 
arrow) of the left infrazygomatic masticator space involving the left medial and lateral 
pterygoid muscles. 
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Figure 14: Masticator space mass with perineural spread. Fused coronal PET/MRI with 
T1-weighted post contrast fat-saturated image shows an infiltrating, FDG avid 
masticator space mass (yellow arrow) with enhancing, mildly FDG avid perineural tumor 
spread along the course of cranial nerve V3 (white arrow). 
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Figure 15: Distant disease. Fused axial PET/MR with T1 VIBE post-contrast fat-
saturated image shows enhancing, FDG avid intramuscular (white arrows) and 
subcutaneous (yellow arrow) nodules suggestive of lymphomatous infiltration. 
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Table 1: Sample oncologic neck soft tissue PET/MRI protocol 
Region 
Scanned 
MRI Sequence Plane Imaging Time Concurrent 
PET 
Acquisition 
Skull vertex to 
mid thighs 






Skull vertex to 
mid thighs 
HASTE Coronal 2 minutes 










Neck T1 TSE Coronal 2 minutes 
Neck T2 FS TSE Axial 3 minutes 
Neck T2 FS TSE Coronal 5 minutes 
Neck T1 TSE FS +C Axial 5 minutes 
Neck T1 TSE FS +C Coronal 3 minutes 
Skull vertex to 
mid thighs 
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Table 2: Sample oncologic facial PET/MRI protocol 
Region 
Scanned 
MRI Sequence Plane Imaging Time Concurrent 
PET 
Acquisition 
Skull vertex to 
mid thighs 






Skull vertex to 
mid thighs 
HASTE Coronal 2 minutes 










Face T1 TSE Coronal 2 minutes 
Face T2 FS TSE 3 
mm 
Axial 3 minutes 
Face T2 FS TSE 3 
mm 
Coronal 5 minutes 
Face T1 TSE FS +C Axial 5 minutes 
Face T1 TSE FS +C Coronal 3 minutes 
Face DWI Axial 2 minutes 
Skull vertex to 
mid thighs 
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Table 3: Sample oncologic PET/MRI brain protocol 
Region 
Scanned 
MRI Sequence Plane Imaging Time Concurrent 
PET 
Acquisition 
Skull vertex to 
mid thighs 






Skull vertex to 
mid thighs 
HASTE Coronal 2 minutes 










Brain T2 FLAIR Axial 2 minutes 
Brain T2 FS TSE Axial 2 minutes 
Brain T1 MPRAGE 3D 5 minutes 
Brain T1 TSE 3mm Axial 3 minutes 
Brain T2 FS TSE Coronal 3 minutes 
Brain T1 TSE 3 mm Coronal 4 minutes 
Brain T2 SPACE 3D 5 minutes 
Brain T1 MPRAGE +C 3D 4 minutes 
Skull vertex to 
mid thighs 
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